MedTrace Logo

Administration of GnRH Antagonist to Oocyte Donation Recipients

NCT00635258 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2008-03-13

No results posted yet for this study

Summary

This prospective and randomized study was performed to evaluate whether the replacement of GnRH agonist by a GnRH antagonist in oocyte donation recipients during endometrial preparation has any impact on pregnancy and implantation rates.

Conditions

  • Pregnancy
  • Embryo Implantation

Interventions

DRUG

triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)

0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.

DRUG

GnRH antagonist (Orgalutran®)

GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.

Sponsors & Collaborators

  • University of Valencia

    collaborator OTHER

  • Centro Ginecologia y Obstetricia.

    lead OTHER

Principal Investigators

  • Raga Francisco, M.D., Ph.D. · Centro Ginecologia y Obstetricia.

Eligibility

Min Age
18 Years
Max Age
34 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00635258 on ClinicalTrials.gov